Literature DB >> 8897457

Suppressed anti-aggregating and cGMP-elevating effects of sodium nitroprusside in platelets from patients with stable angina pectoris.

Y Y Chirkov1, L P Chirkova, J D Horowitz.   

Abstract

Platelet hyperactivity plays an important role in the pathogenesis of cardio-vascular diseases. In patients with stable angina pectoris, we have recently demonstrated that nitroglycerin suppressed the increased platelet aggregability. The anti-aggregating effect of NTG and other nitrovasodilators is mediated by platelet guanylate cyclase, which generates cyclic GMP (cGMP) in response to nitric oxide (NO) liberated from the nitrovasodilator molecule. In the current study we utilised a more "direct" NO donor, sodium nitroprusside (SNP), to examine reversal of ADP-induced platelet aggregation in comparison with intraplatelet cGMP elevation in platelets from normal subjects (n = 22) and patients with stable angina pectoris (n = 23). Concentrations of SNP associated with 50% reversal of aggregation were 2.7 +/- 0.4 x 10(-7) mol/L with normal subjects and 4.5 +/- 0.5 x 10(-6) mol/L with patients (P < 0.01). SNP produced a concentration-dependent elevation of intraplatelet cGMP content: with 10(-4) mol/L SNP this was 17-fold for normals and 5-fold for patients (P < 0.01). An increase in cAMP content was seen only with 10(-4) mol/L SNP, and was 157 +/- 11% of baseline in platelets from normal subjects and 138 +/- 14% in patients. There was a strong interrelationship between cGMP-stimulating and anti-aggregating effects of SNP. The decrease in cGMP responsiveness to SNP was not related to a dysfunction of platelet guanylate cyclase; neither basal nor SNP-stimulated activity of the enzyme varied significantly between normal subjects and patients. Lipophilic derivatives of cGMP (db-cGMP) and cAMP (db-cAMP) caused reversal of aggregation; there was a nonsignificant trend towards decreased responsiveness of platelets from patients to both db-cGMP and db-cAMP. The observed decrease in responsiveness of platelets from angina patients to anti-aggregating effects of the exogenous NO donor, SNP, can therefore be attributed to suppressed cGMP accumulation. These results imply reduced platelet sensitivity to endogenous NO (endothelium-derived relaxing factor): this might contribute to platelet hyperaggregability observed in angina pectoris.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8897457     DOI: 10.1007/bf00168445

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  17 in total

1.  Reversal of abnormal platelet aggregability and change in exercise tolerance in patients with angina pectoris following oral propranolol.

Authors:  W H Frishman; B Weksler; J P Christodoulou; C Smithen; T Killip
Journal:  Circulation       Date:  1974-11       Impact factor: 29.690

2.  Increase in reactivity of human platelet guanylate cyclase during aggregation potentiates the disaggregating capacity of sodium nitroprusside.

Authors:  Y Y Chirkov; N N Belushkina; I A Tyshchuk; I S Severina; J D Horowitz
Journal:  Clin Exp Pharmacol Physiol       Date:  1991-07       Impact factor: 2.557

3.  Antiplatelet effects of nitroglycerin in healthy subjects and in patients with stable angina pectoris.

Authors:  Y Y Chirkov; J I Naujalis; R E Sage; J D Horowitz
Journal:  J Cardiovasc Pharmacol       Date:  1993-03       Impact factor: 3.105

Review 4.  Nitric oxide and nitrovasodilators: similarities, differences and potential interactions.

Authors:  T J Anderson; I T Meredith; P Ganz; A P Selwyn; A C Yeung
Journal:  J Am Coll Cardiol       Date:  1994-08       Impact factor: 24.094

Review 5.  Modulation of platelet function by free radicals and free-radical scavengers.

Authors:  D Salvemini; R Botting
Journal:  Trends Pharmacol Sci       Date:  1993-02       Impact factor: 14.819

6.  Platelet hyperaggregability across the coronary bed in response to rapid atrial pacing in patients with stable coronary artery disease.

Authors:  J G Diodati; R O Cannon; S E Epstein; A A Quyyumi
Journal:  Circulation       Date:  1992-10       Impact factor: 29.690

7.  Reversal of human platelet aggregation by low concentrations of nitroglycerin in vitro in normal subjects.

Authors:  Y Y Chirkov; J I Naujalis; S Barber; R E Sage; D W Gove; J K Brealey; J D Horowitz
Journal:  Am J Cardiol       Date:  1992-09-15       Impact factor: 2.778

8.  Age, cardiovascular risk factors and coronary heart disease as determinants of platelet function in men. A multivariate approach.

Authors:  W Terres; K Weber; W Kupper; W Bleifeld
Journal:  Thromb Res       Date:  1991-06-15       Impact factor: 3.944

9.  Impaired responsiveness of platelets from patients with stable angina pectoris to antiaggregating and cyclicAMP-elevating effects of prostaglandin E1.

Authors:  Y Y Chirkov; L P Chirkova; R E Sage; J D Horowitz
Journal:  J Cardiovasc Pharmacol       Date:  1995-06       Impact factor: 3.105

10.  Inhibitory effect of nitroglycerin and sodium nitroprusside on platelet activation across the coronary circulation in stable angina pectoris.

Authors:  J G Diodati; R O Cannon; N Hussain; A A Quyyumi
Journal:  Am J Cardiol       Date:  1995-03-01       Impact factor: 2.778

View more
  5 in total

1.  Preservation of platelet responsiveness to nitroglycerine despite development of vascular nitrate tolerance.

Authors:  Andrew S Holmes; Yuliy Y Chirkov; Scott R Willoughby; Susan Poropat; Jeremy Pereira; John D Horowitz
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

2.  Thrombospondin-1 is an inhibitor of pharmacological activation of soluble guanylate cyclase.

Authors:  Thomas W Miller; Jeff S Isenberg; David D Roberts
Journal:  Br J Pharmacol       Date:  2010-03-03       Impact factor: 8.739

3.  Prolonged suppression of the anti-oxidant/anti-inflammatory effects of BNP post-Takotsubo syndrome.

Authors:  Saifei Liu; Doan Ngo; Yuliy Chirkov; Jeanette Stansborough; Cher-Rin Chong; John D Horowitz
Journal:  ESC Heart Fail       Date:  2020-06-29

Review 4.  Impairment of Anti-Aggregatory Responses to Nitric Oxide and Prostacyclin: Mechanisms and Clinical Implications in Cardiovascular Disease.

Authors:  Yuliy Y Chirkov; Thanh H Nguyen; John D Horowitz
Journal:  Int J Mol Sci       Date:  2022-01-18       Impact factor: 5.923

Review 5.  The prothrombotic tendency in metabolic syndrome: focus on the potential mechanisms involved in impaired haemostasis and fibrinolytic balance.

Authors:  Isabella Russo
Journal:  Scientifica (Cairo)       Date:  2012-08-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.